These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25045435)

  • 1. Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.
    Woopen H; Pietzner K; Richter R; Fotopoulou C; Joens T; Braicu EI; Mellstedt H; Mahner S; Lindhofer H; Darb-Esfahani S; Denkert C; Sehouli J
    J Gynecol Oncol; 2014 Jul; 25(3):221-8. PubMed ID: 25045435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of epithelial cell adhesion molecule in paired tumor samples of patients with primary and recurrent serous ovarian cancer.
    Pietzner K; Woopen H; Richter R; Joens T; Braicu EI; Dimitrova D; Mellstedt H; Darb-Esfahani S; Denkert C; Lindhofer H; Fotopoulou C; Sehouli J
    Int J Gynecol Cancer; 2013 Jun; 23(5):797-802. PubMed ID: 23694980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
    Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
    Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer.
    Tas F; Karabulut S; Serilmez M; Ciftci R; Duranyildiz D
    Tumour Biol; 2014 Apr; 35(4):3095-102. PubMed ID: 24307621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of epithelial cell adhesion molecule in ovarian cancer patients.
    Lee M
    J Gynecol Oncol; 2014 Oct; 25(4):352-4. PubMed ID: 25310035
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
    Steffensen KD; Smoter M; Waldstrøm M; Grala B; Bodnar L; Stec R; Szczylik C; Jakobsen A
    Int J Oncol; 2014 May; 44(5):1736-44. PubMed ID: 24585004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
    Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of epithelial cell adhesion molecule protein is associated with favorable prognosis in an unselected cohort of ovarian cancer patients.
    Battista MJ; Cotarelo C; Jakobi S; Steetskamp J; Makris G; Sicking I; Weyer V; Schmidt M
    J Cancer Res Clin Oncol; 2014 Jul; 140(7):1097-102. PubMed ID: 24728493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.
    Heubner M; Errico D; Kasimir-Bauer S; Herlyn D; Kimmig R; Wimberger P
    Med Oncol; 2011 Jun; 28(2):626-30. PubMed ID: 20383668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of MAGE-A9 Is Predictive of Poor Prognosis in Epithelial Ovarian Cancer.
    Xu Y; Wang C; Zhang Y; Jia L; Huang J
    Sci Rep; 2015 Jul; 5():12104. PubMed ID: 26175056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.
    Smoter M; Bodnar L; Grala B; Stec R; Zieniuk K; Kozlowski W; Szczylik C
    J Exp Clin Cancer Res; 2013 Apr; 32(1):25. PubMed ID: 23631819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
    Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
    Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
    Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor.
    Bamias A; Sotiropoulou M; Zagouri F; Trachana P; Sakellariou K; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Eur J Cancer; 2012 Jul; 48(10):1476-83. PubMed ID: 22047635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.
    Spizzo G; Went P; Dirnhofer S; Obrist P; Moch H; Baeuerle PA; Mueller-Holzner E; Marth C; Gastl G; Zeimet AG
    Gynecol Oncol; 2006 Nov; 103(2):483-8. PubMed ID: 16678891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Practice of Adjuvant Chemotherapy in Patients with Early-Stage Epithelial Ovarian Cancer.
    Frielink LM; Pijlman BM; Ezendam NP; Pijnenborg JM
    Chemotherapy; 2016; 61(6):287-94. PubMed ID: 27074010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer.
    Pylväs-Eerola M; Karihtala P; Puistola U
    BMC Cancer; 2015 Jul; 15():493. PubMed ID: 26134400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.